National Institutes of Health
The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system.The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to four years and will support research that is in the final states of preclinical development with potential for near-term clinical development. The total duration of both R61 and R33 cannot exceed five years. The R33 is to focus on advancing a single therapeutic candidate through Investigational New Drug or Investigational Device Exemption (IND/IDE) enabling studies, filing an IND/IDE package with the FDA, and designing future clinical trials. R33 recipients must submit or obtain an IND/IDE application to FDA, or must transition the product to clinical practice, within the period of performance. The specific activities appropriate for the R33 phase will depend on the product under study and available preliminary data on the product. Delineation of milestones by the applicant for the R61 and R33 phases is a key characteristic of this program. A milestone is defined as a scheduled event in the project timeline that signifies the completion of a major project stage or activity. This program will support applications that propose a series of milestones including manufacturing and product development goals. Applications that address contingency plans to proactively confront potential delays in meeting the milestones are strongly encouraged. Milestones are required for both phases. Milestones must be specific, measurable, achievable, relevant, and time-bound (SMART). All projects will begin with a R61 phase regardless of therapeutic starting point.
Varies, see official page
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Who can apply: Schools & Colleges, Government & Tribal, Nonprofits, Small Businesses, For-Profit Businesses
Nationwide (USA)
Federal Government
Apply through Grants.gov. Your organization needs active SAM.gov (UEI) and Grants.gov registrations, these can take several weeks, so start early.
Substance Abuse and Mental Health Services Adminis
The purpose of this program is to support organizations in mobilizing and connecting community resources to increase access to long-term recovery support for people with substance use disorders and co-occurring substance use and mental disorders.
Last verified Oct 19, 2026
Centers for Disease Control and Prevention - ERA
The purpose of the R01 grant program is to (1) improve understanding of the risks and conditions associated with occupational diseases and injuries, (2) identify and evaluate methods to reduce risks and prevent or minimize exposure to hazardous workplace conditions, and (3) translate scientific findings into practical prevention strategies, interventions, and products that reduce work-related illnesses and injuries. The Research Project Grant (R01) supports a discrete, specified research project in scientific areas that reflect the investigator's expertise and interests and that align with the mission of NIOSH. Applicants must concisely describe the occupational health problem their proposal addresses and explain how the proposed research activities will lead to outputs that help address this problem. Applicants should clearly describe the expected impacts of the proposed research, both during the project period and beyond.
Last verified Oct 19, 2026
Office of Naval Research
Established in 1985, the Department of War Multidisciplinary University Research Initiative (MURI) program funds U.S. academic research teams to conduct high-impact basic research that addresses future challenges faced by the Department of War. The MURI program specifically supports U.S. university teams investigating complex, DoW-relevant problem sets at the intersection of multiple scientific disciplines. MURI teams bring together world-class faculty, postdoctoral researchers, and graduate students - helping to develop a technically advanced, defense-aware scientific workforce and strengthen the U.S. defense industrial base.
Last verified Oct 19, 2026
Centers for Disease Control and Prevention - ERA
This Notice of Funding Opportunity (NOFO) supports research to develop, implement, monitor, and evaluate technology-driven and cost-effective tools that reduce the global human rabies burden. It also measures progress toward canine rabies elimination, with an emphasis on high-burden countries. Priority research areas include: Electronic systems for tracking human and dog rabies vaccinations. Managing human rabies exposure investigations. Enhancing rabies laboratory information management systems. Modeling the economic impact of dog-mediated rabies interventions. Estimating rabies-susceptible dog populations. The research is intended to generate data-driven strategies that help accelerate progress toward global canine rabies elimination and protect public health.
Last verified Oct 19, 2026